BioNTech, OncoC4 collaborate to co-develop and commercialize novel checkpoint antibody in multiple solid tumor indications Ruchika Sharma21 March 2023 8:45 AM GMTUnder the terms of the agreement, OncoC4 will receive a $200 million upfront payment and is eligible to receive development, regulatory and commercial...
Pfizer gets USFDA emergency use nod for Omicron BA.4/BA.5-adapted bivalent COVID booster in children under 5 years Ruchika Sharma15 March 2023 6:45 AM GMTThe Pfizer-BioNTech COVID-19 Vaccines (COMIRNATY) are based on BioNTech's proprietary mRNA technology and were developed by both BioNTech and Pfizer.
Pfizer, BioNTech submit application to USFDA for emergency use nod of Omicron BA.4/BA.5-adapted bivalent COVID booster in children under 5 years Ruchika Sharma2 March 2023 10:45 AM GMTNew York: Pfizer Inc. and BioNTech SE have submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use...
Pfizer, BioNTech seek USFDA nod for Omicron BA.4/BA.5-Adapted Bivalent COVID vaccine for ages 12 years and older as primary series or booster Ruchika Sharma25 Feb 2023 7:00 AM GMTNew York: Pfizer Inc. and BioNTech SE have announced that they have submitted a supplemental Biologics License Application (sBLA) to the U.S....
Clinical trials for BioNTech cancer vaccines should start this year in Britain: Ugur Sahin Ruchika Sharma21 Feb 2023 8:00 AM GMT"We believe that this should be possible for large amounts of patients before 2030," Sahin said.
BioNTech begins clinical trial of mRNA-based malaria vaccine candidate Ruchika Sharma25 Dec 2022 6:45 AM GMTThe company said it will initially evaluate different antigens of the parasite that causes malaria over the coming months to help select the...
Moderna fires back at Pfizer counterclaims in COVID vaccine patent lawsuit Ruchika Sharma24 Dec 2022 7:00 AM GMTModerna asked for an undisclosed amount of money damages from Pfizer COVID-19 vaccines sold since March.
Pfizer, BioNTech countersue Moderna over COVID-19 vaccine patents Ruchika Sharma6 Dec 2022 8:00 AM GMTPfizer and BioNTech said in their Monday filing that they developed their vaccine independently, calling Moderna's lawsuit "revisionist history" and...
Pfizer, BioNTech seek USFDA emergency use nod for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in children under 5 years Ruchika Sharma6 Dec 2022 6:00 AM GMTNew York: Pfizer and BioNTech have announced that the companies have submitted an application to the U.S. Food and Drug Administration (USFDA) for...
BioNTech, Ryvu Therapeutics ink pact for Immuno-Modulatory Small Molecule Candidates Ruchika Sharma4 Dec 2022 7:00 AM GMTUnder the terms of the agreement, BioNTech will pay Ryvu an upfront fee of €20 million in exchange for certain rights to Ryvu’s STING agonist...
BioNTech affiliate to acquire Novartis GMP-certified manufacturing facility in Singapore Ruchika Sharma15 Nov 2022 11:02 AM GMTSingapore: BioNTech SE has announced its Singapore affiliate BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. had entered into an agreement...
Pfizer, BioNTech get positive CHMP opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID vaccine booster for children 5 through 11 years of age in EU Ruchika Sharma13 Nov 2022 8:30 AM GMT-New York: Pfizer Inc. and BioNTech SE have announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY...
